Scott Got­tlieb has a new board po­si­tion to add to the re­sume — and this one is fo­cused on a fa­vorite sub­ject

Scott Got­tlieb has an­oth­er po­si­tion to add to his lengthy ros­ter of boards and ad­vi­so­ry roles in the wake of his de­par­ture from the helm of the FDA.

He’ll be join­ing the ad­vi­so­ry board of Faster­Cures, a think tank which for­mer junk bond king Michael Milken set up to help dri­ve more drugs to the mar­ket, look­ing to ac­cel­er­ate drug R&D. That’s a sub­ject close to the heart of Got­tlieb, who blazed a trail at the FDA fo­cused on hus­tling up the process. That helped en­dear him to the in­dus­try, mak­ing him one of the most pop­u­lar com­mis­sion­ers in FDA his­to­ry.

It’s al­so like­ly to be a much less con­tro­ver­sial post than his board po­si­tion at Pfiz­er, which stirred crit­i­cism from De­mo­c­ra­t­ic pres­i­den­tial can­di­date Eliz­a­beth War­ren.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER